Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from VRTX

3 Biotech Stocks With Strong Value in August

The biotech industry is ascending with growing R&D initiatives, an upsurge in personalized medicine, and enhanced drug formulations, coupled with the incorporation of technological advancements. So, it seems wise to invest in discounted biotech stocks Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Alkermes (ALKS) this month. Keep reading….

StockNews.com

Dow Jones Futures Fall On U.S. Debt Downgrade; AMD, ELF Lead 7 Earnings Movers

Futures fell as Fitch downgraded the U.S. debt rating. AMD and ELF Beauty were big earnings movers late

Investors Business Daily

Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News

Vertex Pharmaceuticals faces numerous catalysts this year and next, an analyst said Wednesday. And VRTX stock popped.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks With 'A' POWR Ratings

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the adoption of emerging technologies. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and United Therapeutics (UTHR) might be solid buys. These stocks are A (Strong Buy) rated in our proprietary…

StockNews.com

3 Momentum Stocks to Buy Now

The market remains volatile amid macroeconomic pressures and fears of an impending recession. However, fundamentally strong stocks Vertex Pharmaceuticals (VRTX), US Foods Holding (USFD), and Vontier (VNT) have gained momentum and could be worth buying. Keep reading.

StockNews.com

Vertex Extends Its Breakout On Better-Than-Expected Profit; Retains Outlook

Vertex Pharmaceuticals retained its full-year outlook and beat quarterly views, pushing VRTX stock higher early Tuesday.

Investors Business Daily

5 S&P 500 Stocks Near Buy Points As Recession Fears Rise

Medical stocks are holding up amid economic and market uncertainty.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

3 Stocks That'll Survive Any Recession

Market experts continue to fear that higher interest rates from the Federal Reserve and the potential for a credit crunch might tip the economy into a recession. Given this backdrop, quality stocks Oracle Corp. (ORCL), Vertex Pharmaceuticals (VRTX), and Humana (HUM) have solid fundamentals that could help them survive a…

StockNews.com

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

StockNews.com

IBD 50 Stocks To Watch: Vertex Pharmaceuticals Nears Buy Point; Institutions Scoop Up Shares

Vertex Pharmaceuticals is forming a base and back above its 50-day moving average. VRTX stock ranks third out of 792 biotechs.

Investors Business Daily

4 Biotech Stocks You Don’t Want to Miss out on in 2023

The biotech industry is growing with considerable developments and government initiatives. Given the solid prospects of the industry, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Exelixis (EXEL), and Cidara Therapeutics (CDTX) could be excellent buys. Keep reading.

StockNews.com

2 Biotech Stocks to Buy Hand Over Fist in March

The biotech industry is expected to expand rapidly, driven by significant advancements and government initiatives. Furthermore, this sector tends to be relatively defensive and holds up relatively well during downturns. So, fundamentally sound biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) might be ideal buys now. Keep reading.

StockNews.com

3 Nasdaq Stocks That Could Carry Your Portfolio for Years

With the broader market in trepidation amid the ongoing turmoil in the banking sector, fundamentally strong and resilient Nasdaq stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Autodesk (ADSK) could be worth investing in for sustained risk-adjusted returns. Continue reading….

StockNews.com

2 Bargain Stocks to Buy For 2023 And Beyond

Despite widespread headwinds, experts believe the U.S. economy might avoid a recession this year. Additionally, value stocks have been outperforming growth, and we think Vertex Pharmaceuticals (VRTX) and Kroger (KR), which seem to be trading at discounts, could be ideal buys for 2023 and beyond. Keep reading.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

5 Biotech Stocks That Could Make You Rich in 10 Years

The biotech industry is rapidly growing amid rising private and government investments and technological advancements. Given the solid prospects of the industry, fundamentally strong biotech stocks Amgen (AMGN), Vertex (VRTX), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be ideal long-term investments for steady returns. Keep reading.

Investors Business Daily

Dow Jones Futures Fall, AI Arms Race Intensifies; Fortinet, Enphase, Uber Jump On Earnings

A Microsoft-Google AI arms race is keeps expanding. Fortinet, Uber and Enphase were big winners early Wednesday.

Investors Business Daily

Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat

Vertex Pharmaceuticals' fourth-quarter sales divided analysts Wednesday as VRTX stock toppled on a lack of near-term catalysts.

StockNews.com

The 5 Best Stocks to Invest $1,000 in Right Now

Improving investors’ sentiments amid the cooling inflation and moderating interest rate increases helped the stock market to surge in recent weeks. Moreover, the IMF raised its world economy growth forecast. Given the rising optimism, AbbVie (ABBV), Vertex Pharmaceuticals (VRTX), Murphy (MUSA), MasterCraft Boat (MCFT), and PrimeEnergy Resources (PNRG) might be…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks to Get in on Before It’s Too Late

Rapidly growing market for personalized medicines and revolutionary technologies like 3D bioprinting is expected to bolster the biotech industry. Moreover, rising government initiatives should support its growth. Hence, quality biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal buys. Continue reading.

Investors Business Daily

Meta, Google, Tesla Lead AI Stocks And More For Weekend Watchlist

Including Meta, Tesla and Google stock, this screen showcases top-rated AI stocks to watch in the Top 20 industry groups.

Investors Business Daily

BP Stock, Baidu Lead 5 Stocks Near Buy Points With Big Growth Potential

BP and Chinese search leader Baidu lead this weekend's watch list of 5 stocks near buy points with strong growth opportunities.

Investors Business Daily

Dow Jones Futures: Netflix Jumps On Subscribers, Google Slashing 12,000 Jobs After Market Rally Breaks Key Levels

The market rally suffered more damage as the S&P 500 fell below its 50-day line. Netflix subscriber growth easily beat. Google will cut 12,000 jobs.

Investors Business Daily

How IBD Stock Of The Day Vertex Is Stacking Up Billions In Potential Sales

Vertex is Wednesday's IBD Stock Of The Day. As the biotech eyes several blockbuster opportunities, VRTX stock is finding renewed support.

Investors Business Daily

Dow Jones Futures Rise On Bank Of Japan Surprise; Tesla, Moderna Lead Early Movers

Futures rose and yields fell as the Bank of Japan stayed dovish. The market rally paused while Tesla stock jumped. United Airlines, Moderna rose overnight. Microsoft job cuts loom.

StockNews.com

The No. 1 Biotech Stock to Buy for 2023

Biotech stock Vertex Pharmaceuticals (VRTX) outperformed its industry peers, gaining more than 30% over the past year. The company reported solid performance in the CF business and across the company in the last quarter. Moreover, VRTX is committed to delivering a diversified pipeline of transformative medicines and therapies. Hence, this…

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.